Toripalimab: all 344 studies that test it
Page 4 of 4. Open to participants first (178), then studies with results posted, then the rest; newest registration first within each.
- Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC PatientsStatus unknownNCT04164238Phase 2
- Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLCCompletedNCT04144608Phase 2
- High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery(RePASS)Status unknownNCT04126460Phase 2
- Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric CancerStatus unknownNCT04119622Phase 2
- A Study for PD-1 Antibody JS001 in MSI-H Advanced or Recurrent Colorectal CancerStatus unknownNCT04118933Phase 2
- Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell CarcinomaCompletedNCT04118855Phase 2
- Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial CarcinomaStatus unknownNCT04099589Phase 2
- Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic TreatmentCompletedNCT04085276Phase 3
- A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.SuspendedNCT04084158Phase 2
- Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor ThrombusStatus unknownNCT04069949Phase 1/2
- HAIC Plus Lenvatinib and Toripalimab for Advanced HCCCompletedNCT04044313Phase 2
- Chidamide Combined With Toripalimab in SarcomaCompletedNCT04025931Phase 2
- Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant TumorsStatus unknownNCT04010071Phase 2
- Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal CancerStatus unknownNCT04006041Phase 2
- Combination of Toripalimab and Chemoradiotherapy in Esophageal CancerCompletedNCT04005170Phase 2
- Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine CarcinomaStatus unknownNCT03992911Phase 2/3
- Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced CholangiocarcinomaStatus unknownNCT03982680Phase 2
- Safety and Efficacy of PD-1 Inhibitors in Patients With Liver TransplantStatus unknownNCT03966209Phase 1
- Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic CholangiocarcinomaStatus unknownNCT03951597Phase 2
- Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic SarcomaStatus unknownNCT03946943Phase 2
- JS001 Combined With Regorafenib in Patients With Advanced Colorectal CancerStatus unknownNCT03946917Phase 1/2
- Phase II Study in the Treatment of Patients With Advanced Mucinous MelanomaStatus unknownNCT03941795Phase 2
- Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With OligometastasisStatus unknownNCT03927898Phase 2
- Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC PatientsActive, not recruitingNCT03925090Phase 2
- Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKICompletedNCT03924050Phase 3
- Phase II of Lenvatinib Plus Toripalimab for Advanced HCCWithdrawnNCT03919383Phase 2
- CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)Status unknownNCT03904719Phase 2
- Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular CarcinomaTerminatedNCT03867370Phase 1/2
- Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical ResectionActive, not recruitingNCT03859128Phase 2/3
- A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLCCompletedNCT03856411Phase 3
- IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.Status unknownNCT03854838Phase 2
- CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).Status unknownNCT03848611Phase 2
- Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed ChemotherapyStatus unknownNCT03811379Phase 2
- ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung CancerCompletedNCT03732664Phase 1
- Compare Neoadjuvant DOS Combined With Toripalimab Versus SOX Combined With Toripalimab in Locally Advanced Gastric AdenocarcinomaActive, not recruitingNCT03691454Phase 2/3
- Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC.WithdrawnNCT03623776Phase 2
- Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.Status unknownNCT03602547Phase 2
- A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic MelanomaCompletedNCT03430297Phase 3
- Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant LymphomaCompletedNCT03316144Phase 1
- The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001CompletedNCT03301688Phase 1
- PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) PatientsStatus unknownNCT03251313Phase 1
- Study of JS001 in Patients With Advanced Neuroendocrine TumorsCompletedNCT03167853Phase 1
- Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid TumorsStatus unknownNCT02836834Phase 1
- Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid TumorsCompletedNCT02836795Phase 1